Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 400.59%.

  • Autolus Therapeutics' EBITDA Margin changed N/A to 400.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 447.55%, marking a year-over-year increase of 19022600.0%. This contributed to the annual value of 2182.25% for FY2024, which is 95066200.0% up from last year.
  • Per Autolus Therapeutics' latest filing, its EBITDA Margin stood at 400.59% for Q3 2025.
  • Autolus Therapeutics' 5-year EBITDA Margin high stood at 17141525.42% for Q3 2021, and its period low was 192696.55% during Q4 2024.
  • Its 5-year average for EBITDA Margin is 1409492.77%, with a median of 589.51% in 2024.
  • In the last 5 years, Autolus Therapeutics' EBITDA Margin skyrocketed by 2000000000bps in 2021 and then crashed by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EBITDA Margin stood at 17141525.42% in 2021, then tumbled by -100bps to 499.73% in 2022, then crashed by -2448bps to 12730.54% in 2023, then crashed by -1414bps to 192696.55% in 2024, then surged by 100bps to 400.59% in 2025.
  • Its EBITDA Margin was 400.59% in Q3 2025, compared to 138.36% in Q2 2025 and 657.9% in Q1 2025.